SWIFT, India’s emerging pharmaceutical Company, that manufactures and markets world-class generics, branded generic pharmaceuticals and visions to manufacture and market active pharmaceutical ingredients (API) in the near future.
Industry competition comes in several forms, the most significant being the companies that choose to do development, production, marketing and distribution of medicines in house. SWIFT can leverage opportunities and manage all challenges that could arise in the domestic Indian market. The structuring of our product portfolio into primary, secondary and tertiary brands will help to create power. New products have a sharper focus with a specialized management team looking into opportunities and launches. SWIFT will grow market share through a combination of new products, innovative selling and brand management.
In licensing and Alliances remain an important component of our strategy for the near to medium term. Given its importance in our strategy, our company has a dedicated management team to source new product and alliances opportunities, both domestically and globally.
Our Company will be committed to maintain its Prescription trend and price lines across key segments.
SWIFT will have strong brand and brand life-cycle management systems designed to derive competitive advantages in one of the most challenging pharmaceutical markets in the world.
The company will have one of the widest product portfolios in India, spanning key therapeutic areas. The company proposes alliances across the globe in key therapeutic areas.
With a sharp the focus on disease areas, the company will have specialist field forces that will cover all key doctor segments. The multi-specialty approach to mass consumption brands and products, which require considerable reach and penetration across the country, will enable SWIFT to derive considerable advantages from skill, scale and size.
Our Company will be committed to maintain its prescription trend and prices across key segments, will help to have a substantial niche in the market.
While the Company would continue to enhance its momentum in the generics business,emphasis on NCEs (New Chemical Entities) for long-term value building in the medium term are the key anchors of future growth.
The Company’s vision is to achieve significant business in proprietary prescription products, with a strong presence in developed markets. It also aspires to be amongst the Top players in the industry.
To translate these objectives into reality and to optimize value creation, the Company has adopted a multi-pronged strategy. Together with the commitment of multicultural workforce, SWIFT will pursue its strategies to become a Center of Innovations.